Clinical trials
Breast Cancer Detection clinical trials
Below are recruiting breast cancer detection clinical trials, each written for real people, not researchers. We’re tracking 258 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05416164Recruiting
Testes less radiation after a complete response to medicines
This study checks whether some people with breast cancer who have no remaining cancer after medicine (neoadjuvant systemic therapy) can safely receive less radiation. It may help reduce side effects while still keeping cancer controlled.
Amsterdam, North HollandAges 18 years+ - NCT07362485Recruiting
Finding sentinel nodes during mastectomy with dye
This trial tests if a special dye (indocyanine green) can find the first lymph nodes (sentinel nodes) during mastectomy. It may help improve staging for women with early breast cancer who need or choose mastectomy.
Zwolle, OverijsselAges 18 years+ - NCT06540872RecruitingPhase 2
Testing New PET/MRI Scan in Large DCIS
This study tests a new imaging method that combines a special PET scan (FAPI) with MRI to see if it can better find hidden invasive cancer in people with large areas of ductal carcinoma in situ (DCIS). It aims to improve surgical planning and avoid second surgeries.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06518135Recruiting
Sentinel node biopsy after chemo for initial node-positive breast cancer
This trial checks whether a less invasive sentinel lymph node biopsy (removing just a few nodes) can safely replace full lymph node removal for people whose breast cancer and underarm lymph nodes responded well to chemotherapy. It is for patients who initially had 1 to 3 involved nodes and now appear cancer-free in the armpit.
Henan, HenanAges 18–70 - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT06468566Recruiting
New imaging test for breast lumps using sound and light
This study tests a new kind of imaging that uses sound waves and light to tell if a breast lump is benign (not cancer) or malignant (cancer). It could help avoid unnecessary biopsies.
Wuhan, HubeiAges 18–85 - NCT06050109Recruiting
Continuing Ovarian Suppression After 5 Years
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Wuhan, HubeiAges 18–60 - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Mobile, AlabamaAges 18–100 - NCT06304168Recruiting
Blood, tissue, and urine tests to detect cancer early
This study is testing whether simple blood, tissue, and urine samples can help find cancer earlier and identify where it started. Participating could help improve future cancer detection for everyone.
Rochester, MinnesotaAges 18 years+ - NCT07708571Recruiting
Coaching program for women on ribociclib and aromatase inhibitor
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
Augsburg, BavariaAges 18 years+ - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT04265872RecruitingEarly Phase 1
Bortezomib then pembrolizumab and cisplatin for metastatic triple-negative breast cancer
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Dallas, TexasAges 18 years+ - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT04994067Recruiting
Registering radiation given during breast-conserving surgery
This study records details about radiation delivered while your surgery is happening for certain early breast cancers or pre-cancers. It may help doctors better understand who benefits most from this “intra-operative” radiation approach.
The Bronx, New YorkAges 18 years+ - NCT05228951RecruitingPhase 2
Testing four breast cancer medicines for stage II–III ER+/PR+/HER2+ cancer
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
Shenyang, LiaoningAges 18–75 - NCT05704166RecruitingPhase 2
Pirfenidone to prevent lung injury after breast radiation
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
Fuzhou, FujianAges 18–75 - NCT06682195RecruitingPhase 2
Chemo plus toripalimab before surgery for TNBC
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
Nanchang, JiangxiAges 18–70 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06786026RecruitingPhase 2
Drug combo plus chemotherapy for first-line advanced triple-negative breast cancer
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06907810Recruiting
Study of fat molecules in long-term breast surgery pain
This trial looks at how certain natural fat molecules in your body might relate to long-term pain after breast cancer surgery. It could help doctors better understand and treat chronic pain in the future.
Brussels, Brussels CapitalAges 18 years+ - NCT06963905RecruitingPhase 1/Phase 2
Testing a combination drug for triple-negative breast cancer
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Breast Cancer Detection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer detection?
- Yes. Clin2 currently lists 258 recruiting breast cancer detection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer detection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer detection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.